Tag: FibroGen
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of...
Study did not meet the primary endpointPamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in...
FGEN FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc....
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on...
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen,...
FGEN DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors...
RADNOR, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that...
FGEN Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders...
RADNOR, Pa., May 31, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that...
Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors...
RADNOR, Pa. , May 23, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that...
HAGENS BERMAN Reminds FibroGen (FGEN) Investors of Securities Fraud Lawsuit and...
SAN FRANCISCO, May 23, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit...
FIBROGEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James...
NEW YORK, May 21, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential...
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces...
RADNOR, Pa., May 15, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their...
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen,...